Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states by Mercedes Prudencio & David R Borchelt
Superoxide dismutase 1 encoding mutations
linked to ALS adopts a spectrum of misfolded
states
Prudencio and Borchelt
Prudencio and Borchelt Molecular Neurodegeneration 2011, 6:77
http://www.molecularneurodegeneration.com/content/6/1/77 (17 November 2011)
RESEARCH ARTICLE Open Access
Superoxide dismutase 1 encoding mutations
linked to ALS adopts a spectrum of misfolded
states
Mercedes Prudencio1,2 and David R Borchelt1*
Abstract
Background: Mutations in superoxide dismutase 1 (SOD1), which are one cause of familial amyotrophic lateral
sclerosis (fALS), induce misfolding and aggregation of the protein. Misfolding can be detected by the binding of
antibodies raised against peptide epitopes that are normally buried in the native conformation, shifts in solubility
in non-ionic detergents, and the formation of macromolecular inclusions. In the present study, we investigate the
relationship between detergent-insoluble and sedimentable forms of mutant SOD1, forms of mutant SOD1 with
aberrantly accessible epitopes, and mutant protein in inclusions with the goal of defining the spectrum of
misfolded states that mutant SOD1 can adopt.
Results: Using combined approaches in cultured cell models, we demonstrate that a substantial fraction of mutant
SOD1 adopts a non-native conformation that remains soluble and freely mobile. We also show that mutant SOD1
can produce multimeric assemblies of which some are insoluble in detergent and large enough to sediment by
ultracentrifugation and some are large enough to detect visually. Three conformationally restricted antibodies were
found to be useful in discriminating mal-folded forms of mutant SOD1. An antibody termed C4F6 displays
properties consistent with recognition of soluble, freely mobile, mal-folded mutant SOD1. An antibody termed
SEDI, which recognizes C-terminal residues, detects larger inclusion structures as well as soluble misfolded entities.
An antibody termed hSOD1, which recognizes aa 24-36, detects an epitope shared by soluble non-natively folded
WT and mutant SOD1. This epitope becomes inaccessible in aggregates of mutant SOD1.
Conclusions: Our studies demonstrate how different methods of detecting misfolding and aggregation of mutant
SOD1 reveal different forms of aberrantly folded protein. Immunological and biochemical methods can be used in
combination to detect soluble and insoluble misfolded forms of mutant SOD1. Our findings support the view that
mutant SOD1 can adopt multiple misfolded conformations with the potential that different structural variants
mediate different aspects of fALS.
Background
One consequence of fALS associated mutations in
SOD1 [Swiss-Prot: P00441] that seems to be shared by
all mutants is that the mutant SOD1 is far more prone
to adopt aberrant conformations that result in its aggre-
gation [1]. This common property is easily assessed in
cultured cell models in which mutant SOD1 is overex-
pressed. However, pathologic evidence of mutant SOD1
aggregation in disease has also been consistently
demonstrated in human fALS patients harboring muta-
tions in SOD1 and transgenic mouse models of this dis-
ease. In both cases, there are multiple reports of the
detection of SOD1 immunoreactive inclusions in spinal
motor neurons [2-13]. For example, in transgenic mouse
models of SOD1-associated ALS, SOD1 antibody reac-
tive inclusions have been detected in spinal motor neu-
rons of mice expressing the H46R [14], G85R [4,10],
and G93A [7,8,10,13] mutants; and in spinal astrocytes
of mice expressing the G85R [4] mutant. However, there
have been reports of poor detection of SOD1-immunor-
eactive inclusions in spinal motor neurons of G37R,
G85R, G93A, H46R/H48Q and Quad SOD1 transgenic
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mice [10,15,16]. Moreover, in mice expressing the G37R
and G93A mutants at levels high enough to cause
paralysis in 4 to 6 months, the more obvious pathology
identified by SOD1 antibodies is a vacuolar pathology
[15,17]. In general, in the aforementioned studies in
which SOD1-immunoreactive inclusions have been
detected, they have generally been found to be most
abundant in end-stage mice.
Misfolded mutant SOD1 can also be detected bio-
chemically, using an assay that involves detergent
extraction and centrifugation followed by western blot-
ting [1,18-21]. In transgenic mouse models of SOD1-
fALS, detergent insoluble forms of mutant SOD1 accu-
mulate to high levels late in the course of disease,
becoming readily detectable at the onset of visible symp-
toms [22]. In the G93A-Gur1 model, which reaches
end-stage paralysis at about 120 days, aggregates begin
to accumulate between 90 and 105 days and then rise
dramatically as the animals approach endstage [22].
During this same interval the levels of neurofilament H
in serum, which serves as a biomarker of axonal degen-
eration [23], also rise dramatically. Thus we can corre-
late aggregation of mutant SOD1 and axonal
degeneration in the animal models. However, it remains
difficult to assign cause and effect as it is possible that
the accumulation of aggregates serves as a biomarker of
cellular degeneration in which the cells simply lose the
ability to prevent the misfolded mutant protein from
aggregating because of some combination of declining
chaperone activities, declining proteasome activity to
degrade the misfolded protein, or declining energy pro-
duction to support these activities. Moreover, in the
best studied G93A model, it is very clear that numerous
pathologic abnormalities can be detected prior to the
accumulation of aggregated mutant SOD1, indicating
that other misfolded forms of mutant SOD1 must med-
iate early events in the evolution of disease [22].
One method that has emerged as a means to specifi-
cally detect misfolded forms of mutant SOD1 involves
SOD1 antibodies raised against specific peptide
sequences that are normally buried in the tertiary struc-
ture of native WT protein or against preparations of
mutant SOD1 [17,24,25]. Some of these antibodies have
the potential to detect a variety of structural variants of
SOD1, including immature unfolded protein, misfolded
soluble protein, and inclusion structures. In a study of
the G93A mouse model, Rakhit et al [17] described an
antibody to sequences in the C-terminus of SOD1,
called the SEDI antibody, which showed minimal reac-
tivity with natively folded WT SOD1. As compared to
tissues from mice expressing WT SOD1, tissues from
symptomatic mice expressing mutant SOD1 (G37R,
G85R, and G93A) contained higher levels of SOD1 pro-
teins that reacted with the SEDI antibody. In tissue
sections from these animals, the SEDI antibody stained
SOD1, accumulating at the rims of vacuolar pathology
in the G37R and G93A mice (more rarely inclusion like
structures were stained) and structures resembling
inclusions in the G85R mice (vacuolar pathology limited
in this model). In presymptomatic G37R and G93A
models, SEDI immunoreactivity was abundant at the
rims of vacuolar pathology that is among the first identi-
fiable pathologic abnormality, occurring well before the
onset of symptoms [17]. Collectively, these studies with
conformationally-restricted antibodies indicate that mis-
folded SOD1 proteins are present early in the evolution
of disease.
In the present study, we have sought to use cell cul-
ture models to investigate the characteristics of the var-
ious forms of misfolded mutant SOD1 proteins and to
investigate the relationships between misfolded SOD1
proteins, detergent insolubility, and inclusions. To
accomplish this goal, we combine the visual capability of
the YFP fusion proteins with biochemical assays of inso-
lubility and with immunohistochemical approaches
using conformationally restricted antibodies. Our find-
ings provide new insight into the spectrum conse-
quences that fALS mutations have on the folding of
SOD1 and how different approaches to detection can be
used to reveal aspects of mutant SOD1 misfolding.
Results
Visualization of misfolded and aggregated mutant SOD1
in cultured cell models
The A4V mutation in SOD1 is associated with rapidly
progressing disease and when expressed in HEK293FT
cells is among the most prone to produce detergent-
insoluble aggregates of mutant protein [1]. To date,
however, we have not sought to visualize whether the
accumulation of detergent-insoluble aggregates is
accompanied by inclusion formation in these cell mod-
els. Following previously established protocols [1,20,21],
HEK293FT cells were transiently transfected with
expression vectors for WT and A4V mutant SOD1, for
24 hours, then fixed and analyzed by immunofluores-
cence staining with the hSOD1 antibody, which was
raised against a synthetic peptide corresponding to resi-
dues 24-36 and which specifically recognizes human
SOD1 protein (hSOD1 antibody) [4]. This antibody can-
not immunoprecipitate natively folded, fully metallated,
WT SOD1 protein and is thus conformationally
restricted (see Supplemental Material in [26]). Com-
pared to untransfected cells (Figures 1A and 1B), cells
expressing either WT (Figures 1C and 1D) or A4V
SOD1 (Figures 1E and 1F) showed diffuse immunofluor-
escence without obvious cytoplasmic inclusions. Within
nuclei of cells transfected with either WT or mutant
SOD1, there were punctate structures that appeared to
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be some concentration of SOD1 in or around nuclear
structures. The significance of these structures is uncer-
tain at present.
In these experiments, the absence of immunoreactivity
by the hSOD1 antibody in the untransfected human
HEK293FT cells may be due partially to relative levels
of protein; in the transfected cells the expressed SOD1
protein is much more abundant and thus at exposures
optimal for visualization of the expressed protein,
untransfected cells were virtually invisible. Additionally,
we expect the endogenous protein to be more fully
metallated and thus less reactive to the hSOD1 antibody
[26]. Therefore, we primarily visualized the over-
expressed SOD1 proteins in these experiments.
In detergent extraction of cells transfected in parallel,
we observed, as previously reported [1,16], an accumula-
tion of detergent-insoluble mutant protein (Additional
File 1, Figure S1). However, only a minority of the total
A4V SOD1 protein that was expressed in these cells was
insoluble in detergent (Additional File 1, Figure S1).
Thus, we expected that either most cells would show
diffuse staining with only a minority having enough
expression to induce inclusion formation, or that there
might be small visible inclusions within a general back-
ground of diffusely distributed mutant protein. The
absence of inclusion detection could also be due to inac-
cessibility of the antibody to its target epitope. As noted
above, the hSOD1 antibody cannot immunoprecipitate
natively folded WT SOD1, but shows strong reactivity
to denatured protein (see Supplemental Material in
[26]). Therefore, we asked whether treating the cells
with 70% formic acid to denature proteins would reveal
hSOD1 immunoreactive inclusions (Additional File 1,
Figure S2). However, we still failed to detect inclusions.
To determine whether we might have better detection
of inclusions in mouse cells, using the human SOD1
specific hSOD1 antibody, we transfected mouse fibro-
blast cultures with the same constructs and immunos-
tained with the same antibody (Additional File 1, Figure
S3). However, we observed the same diffuse immunos-
taining pattern that was observed in the HEK293FT
cells.
We next examined HEK293FT cells expressing WT
and mutant A4V SOD1 proteins by immunostaining
cells with additional SOD1 antibodies that have been
described as conformationally-restricted in binding
SOD1 protein. One antibody used was the SEDI SOD1
antibody, which recognizes amino acids 143 to 151 in
the dimer interface of SOD1; these residues are nor-
mally buried within the native protein [17]. Another
antibody used was the C4F6 antibody, which was raised
against the human G93A variant of SOD1 and which
has been described to have very low immunoreactivity
to native WT SOD1 in favor of mutant SOD1 [27]. For
WT SOD1 expressing cells, SEDI immunoreactivity was
generally much lower, although a few cells were found
to be highly reactive (Figures 2A and 2B). Similarly, cells
expressing WT SOD1 showed limited reactivity with the
C4F6 antibody (Figures 2C and 2D). In cells expressing
A4V hSOD1, immunoreactivity to SEDI largely appeared
as uniform fluorescence; similar to the few immunoreac-
tive WT expressing cells (Figures 2E and 2F). Rarely, we
were able to find what appeared to be inclusion struc-
tures (Figure 2E and 2F, inset). Immunostaining of cells
expressing A4V hSOD1 with the C4F6 antibody gave
images similar to those observed with SEDI antibody
(Figures 2G and 2H), infrequently finding cells that con-
tained intracellular inclusion-like structures (Figures 2G
and 2H, inset). Overall, regardless of which antibody
was used, immunoreactive inclusion structures were rare
in cells expressing untagged A4V hSOD1. As noted
above, the majority of SOD1 in cultures expressing A4V
SOD1 was soluble in detergent (see Additional File 1,
Figure 1 HEK293FT cells expressing mutant SOD1 proteins do
not form visible cellular inclusions. A-I) Cells were cultured on
glass coverslips previously coated with 0.5 mg/ml poly-L-lysine
untransfected (A, B), or transfected with expression plasmids for WT
(C, D) or A4V (E, F) SOD1 for 24 hours. Fixed cells were stained with
hSOD1 antibody overnight. A secondary fluorescent (594 nm)
antibody was used to visualize SOD1 antibody binding. Co-staining
with 4’,6-diamidino-2-phenylindole (DAPI) was performed together
with secondary antibody incubations. Pictures were taken with a
100× immersion oil objective, scale bar = 20 μm. Note that at the
same exposure, the staining of overexpressed hSOD1 protein is
much brighter than that of untransfected cells (compare figure A to
C and E). The images shown are representative of at least 3
independent transfection experiments.
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Figure S1). Thus, these cells accumulate a form of
mutant SOD1 that is soluble in non-ionic detergents
and yet is reactive to antibodies that bind epitopes nor-
mally buried in the native conformation of WT SOD1.
Relationship between inclusions and detergent-insoluble
SOD1
To more easily visualize which cells express mutant
SOD1 and which cells develop inclusions, we generated
variants of SOD1 tagged with yellow fluorescent protein
(YFP). Multiple laboratories have used similar
approaches to visualize inclusions formed by mutant
SOD1 in living cells using fluorescent proteins such as
green fluorescent protein (GFP), YFP, red fluorescent
protein (RFP), or DsRed2 in various cultured cell models
[28-35]. Thus we created several SOD1::YFP constructs
to express in cultured cells as a means to analyze the
relationships between detergent-insoluble aggregates
that can be detected biochemically and visible cellular
inclusions. We used two cell models for these studies;
the previously described HEK293FT cell model [1,20,21]
and Chinese Hamster Ovary cells (CHO cells). Transient
transfections of WT SOD1 tagged with YFP (WT::YFP)
in HEK293FT for 24 hours showed uniform distribu-
tions of fluorescence throughout the cytosol (Figure
3A). SOD1::YFP fusion proteins generated from the
A4V and G37R variants of SOD1 (A4V::YFP and G37R::
YFP) frequently produced cytosolic inclusion-like struc-
tures (Figure 3A). Notably, not all cells produced inclu-
sions and there were many examples of cells with
diffusely distributed YFP fluorescence. This outcome
may be explained by the non-homogenous expression of
transiently transfected cells; we presume, but cannot
definitively prove, that only the cells with very high
levels of expression develop inclusions. The appearance
of inclusions was accompanied by the accumulation of
significant amounts of detergent-insoluble mutant fusion
proteins (Figure 3B). Notably, cells expressing WT::YFP
SOD1 also accumulated significant amounts of deter-
gent-insoluble fusion protein. However, the relative
aggregation propensity of WT::YFP SOD1 protein was
much lower than that of the mutants (Figure 3C). We
observed a similarly high frequency of inclusions in cells
expressing other fALS mutants of SOD1 and YFP
(G85R::YFP, D101N::YFP, S134N::YFP), with similar
accumulations of detergent insoluble fusion protein
(Additional File 1, Figure S4).
To examine the relationship between inclusion forma-
tion and the formation of detergent-insoluble structures,
we compared the levels of insoluble untagged SOD1 and
SOD1::YFP fusion proteins that accumulate in our trans-
fected cells (Figure 4). As compared to cells expressing
WT SOD1, cells expressing WT::YFP SOD1 fusions
accumulated significantly higher levels of insoluble
SOD1 at 24 (Figures 4A and 4B) and 48 (Figures 4C
and 4D) hours after transfection. However, despite the
accumulation of such large amounts of detergent-insolu-
ble SOD1 we did not observe inclusion structures in
cells expressing WT::YFP fusions (Figures 4E and 4F).
By contrast, in cells expressing A4V::YFP fusions, inclu-
sion structures were visible in 24 hours, becoming more
abundant at 48 hours (Figures 4G and 4H). Relative to
WT::YFP fusions, the level of insoluble protein (ratio of
insoluble to soluble) in cells expressing A4V::YFP
fusions was substantially higher at both 24 and 48
hours. Still, the amount of detergent-insoluble WT::YFP
Figure 2 SEDI and C4F6 antibodies recognize diffusely distributed cytosolic mutant SOD1 in transiently transfected HEK293FT cells.
Cells were transiently transfected with expression plasmids for WT (A-D) or A4V (E-H) SOD1 for 24 hours and stained with SEDI or C4F6
antibodies as explained in Methods. Pictures were taken with a 40× objective. Scale bars = 20 μm. Inset, image of rare cell with inclusion like
structures. The images shown are representative of at least 3 independent transfection experiments.
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fusion protein that accumulated at 48 hours was similar
to cells expressing A4V::YFP fusion for 24 hours (Fig-
ures 4A-D) but only the latter was able to form numer-
ous visible inclusions (Figures 4G and 4H). We interpret
this outcome as evidence that the WT::YFP SOD1
fusion proteins are capable of forming detergent-insolu-
ble structures that are distinct from insoluble inclusions.
Conformationally restricted antibodies to SOD1
With the ability to easily visualize which cells express
mutant SOD::YFP fusion proteins and which cells pro-
duce inclusions, we sought to determine the efficacy
with which different conformationally restricted SOD1
antibodies detect inclusions. For this study, we used the
same three antibodies described above (hSOD1, SEDI
and C4F6). WT::YFP SOD1 expressing cells immunos-
tained with hSOD1 antibody showed uniform cytosolic
distribution (Figures 5A-C), indicating a portion of the
expressed protein did not achieve a native conformation.
In cells expressing A4V::YFP proteins, we observed the
formation of inclusions containing A4V::YFP SOD1,
however the hSOD1 antibody appeared to recognize
only diffusely dispersed A4V::YFP protein (Figures 5D-
F). Although hSOD1 did not appear to directly detect
inclusion structures, we could identify several features in
which it appeared that hSOD1 antibody recognized pro-
tein that appeared to be concentrated around the sur-
face of the inclusion (Figure 5E, arrows). Thus, we
conclude that the sequence recognized by the hSOD1
antibody (residues 24-26) is inaccessible in mutant
SOD1 that is compartmentalized in inclusion structures.
The SEDI and C4F6 antibodies also recognized diffu-
sely distributed SOD::YFP proteins in the cytosol,
including, more infrequently, WT::YFP fusion proteins
Figure 3 Mutant SOD::YFP proteins form visible inclusions in cell culture. A) HEK293FT cells, on poly-L-lysine coated glass coverslips, were
transfected for 24 hours as described in Methods. Cells were fixed and observed under a fluorescence microscope. All pictures were taken using
a 40x objective, scale bars = 50 μm. The images shown are representative of at least 3 independent transfections for each construct. B)
Immunoblot of P2 and S1 protein fractions of cells expressing SOD1::YFP proteins for 24 hours. The SOD1::YFP protein migrates at a size of
approximately 50 kDa (filled arrowhead), while endogenous WT SOD1 monomer runs at 16 kDa (open arrowhead). C) Quantification of the
aggregation propensity (P2/S1) of cells expressing SOD1::YFP proteins (see Methods). As expected, cells transfected with WT::YFP or mutant
SOD1::YFP accumulated much more insoluble protein than untransfected cells: *p ≤ 0.05; #p ≤ 0.005. The aggregation propensity of A4V::YFP
and G37R::YFP were both statistically greater than that of WT::YFP (#p ≤ 0.005). The data were averaged from at least 3 independent repetitions
of each transfection and immunoblot.
Prudencio and Borchelt Molecular Neurodegeneration 2011, 6:77
http://www.molecularneurodegeneration.com/content/6/1/77
Page 5 of 18
(Figures 5G-I, and 5M-O). In cells expressing A4V::YFP,
the SEDI antibody was highly reactive with inclusion-
like structures (Figures 5J-L). The C4F6 antibody
showed moderate reactivity with diffusely distributed
WT::YFP fusion protein in a small subset of cells (Fig-
ures 5M-O), but showed strong reactivity to diffusely
distributed A4V::YFP fusion protein (Figures 5P-R). We
did not observe immunostaining of inclusions with the
C4F6 antibody, thus the epitope recognized by C4F6
antibody is normally buried when the mutant SOD1::
YFP proteins form inclusion structures whereas the epi-
tope of the SEDI antibody is exposed.
Mutant SOD1 inclusions and detergent-insoluble SOD1
are not freely mobile in cytosol
A previous study by Urushitani et al examined mouse
N2a cells expressing mutant SOD1-EGFP fusion pro-
teins, finding that digitonin released most of the
expressed protein but in cells expressing mutant SOD1-
EGFP, punctate inclusion-like structures remained cell
associated [34]. We applied the same technique to our
cell models. Similar to digitonin, saponin is a mild
detergent that open pores on the cellular membranes
without completely lysing the cells, allowing soluble pro-
teins to diffuse out of the cell [36]. In this experiment,
CHO cells were used because these cells were less
prone to dislodge after saponin treatment. Cells trans-
fected with a vector for A4V::YFP fusion proteins pro-
duced characteristic punctate inclusions that were not
released into culture medium by saponin (Figures 6A-D,
and 6M-P). By contrast, WT::YFP fusion proteins
showed a more diffuse localization (Figures 6E-H, and
6Q, R) and this fluorescence was completely released by
saponin treatment (Figures 6G and 6H). Note that a sig-
nificant fraction of WT::YFP SOD1, shown above in Fig-
ure 3, is insoluble in non-ionic detergent and yet
virtually all of the fluorescence is released from these
cells by saponin. In cells expressing YFP alone, fluores-
cence was similarly diffusely distributed with saponin
releasing most of the fluorescence into the medium
(Figures 6I-L, and 6S, T). However, some localization of
the YFP to nuclei was observed and this nuclear protein
was not released by saponin (Figures 6K, L, T). These
findings indicate that the general distribution of inclu-
sion structures does not obviously change with saponin
treatment, suggesting the structures are bound to immo-
bile elements within the cytosol [36].
Based on the immobility of mutant SOD1::YFP inclu-
sions, we once again revisited the detection of mutant
SOD1 aggregates generated by untagged mutant protein
in transfected HEK293FT cells by asking whether treat-
ment of cells with saponin will unmask inclusions in
cells expressing untagged A4V SOD1. Saponin treat-
ment efficiently extracted nearly all of the cytosolic
SOD1 immunoreactivity in cells expressing WT SOD1
(Figures 7A and 7B). The only remaining hSOD1 immu-
noreactive protein was concentrated in, or possibly
around, the nucleus (Figures 7A and 7B). This latter
Figure 4 Analysis of detergent solubility and inclusion formation
in cells co-expressing WT and mutant SOD1. HEK293FT were
transfected with the indicated SOD1 constructs for 24 (A, B, E, G) or 48
(C, D, F, H) hours as noted above the figure. A, C) Immunoblots of P2
and S1 fractions of HEK293FT cells co-transfected with the indicated
SOD1 constructs for 24 (A) or 48 (C) hours and immunoblotted with a
SOD1 antibody. Tagged SOD1::YFP proteins migrate on SDS-PAGE at
relative molecular mass of 50 kDa, while untagged SOD1 variants
migrate at about 16 kDa. B, D) Quantification of the aggregation
propensities (P2/S1) of tagged and untagged proteins from singly or
doubly transfected cells at 24 (B) and 48 (D) hours. Statistical
comparisons were calculated through unpaired student t-tests, *p ≤
0.05, #p ≤ 0.005. The data were averaged from at least 3 independent
transfection and immunoblotting experiments. E-H) Cells transfected
for 24 (E, G) or 48 hours (F, H) were fixed and visualized under a
confocal microscope. Scale bars = 20 μm. The images shown are
representative of at least 3 independent transfection experiments.
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Figure 5 Immunostaining of cells expressing SOD1::YFP fusion proteins with conformationally restricted SOD1 antibodies. HEK293FT
were transfected with WT::YFP or A4V::YFP constructs, as noted on the Figure, and stained with hSOD1 (A-F), SEDI (G-L) or C4F6 (M-R) antibodies
as explained in Methods. Pictures were taken using a 60× water immersion objective of a spinning disc confocal microscope, scale bars = 10
μm. Arrows indicate the location of SOD1::YFP inclusions and the absence of antibody staining. The images shown are representative of at least
3 independent transfection experiments.
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finding is indicative of the small size of SOD1, which
would facilitate passive diffusion into the nucleus [37],
and is consistent with prior observations that SOD1 is
found in nuclear compartments [38]. Despite removing
most of the cytoplasmic immunoreactivity, it was still
difficult to identify cells containing obvious inclusions in
cells expressing A4V hSOD1 (Figures 7C and 7D). Very
rarely we observed small punctate structures in a peri-
nuclear location (Figures 7C and 7D, arrow heads).
We also investigated the expression of mutant human
SOD1 in mouse TK-L cells, in which we could use anti-
bodies specific for human SOD1 to potentially more spe-
cifically visualize inclusions formed by mutant human
SOD1. However, after treatment with digitonin, we
observed immunoreactive structures in cells transfected
mutant hSOD1 that were similar to what we observed in
cells expressing WT SOD1 (Additional File 1, Figure S5).
To verify that aggregated forms of untagged SOD1
were not released by saponin treatment, cells treated
with saponin were subjected to detergent extraction and
centrifugation assay before immunoblotting soluble and
insoluble fractions (Figure 8), following previously
described procedures [1,20,21]. As expected, saponin
treatment induced the release of a significant amount of
both WT and mutant SOD1 protein into the cell culture
media (Figures 8A and 8B). In the case of cells trans-
fected with WT SOD1, a substantial portion of SOD1
protein was released into the media with the fraction
remaining with the cell exhibiting near complete solubi-
lity in detergent (Figures 8A and 8B). A minor fraction
of the WT SOD1 was insoluble in detergent and there
was no significant change in the solubility of WT SOD1
after saponin treatment (Figure 8B). In cells expressing
A4V SOD1, the levels of SOD1 released by saponin
Figure 6 Inclusions formed by mutant SOD1::YFP proteins are not released by saponin treatment. CHO cells were transiently transfected
with expression plasmids for YFP, WT::YFP, and A4V::YFP as noted in the figure and then, after 24 hours, treated with saponin, fixed in 4%
paraformaldehyde, stained with DAPI, and imaged. A, B, E, F, I, J, M, N, Q, R, and S were not treated with saponin. C, D, G, H, K, L, O, P, and T
were treated with saponin. Scale bars in A-L are 50 μm. The images in M-T are digitally magnified cells from A-L. Because saponin completely
extracted all cyotosolic fluorescence from cell expressing WT::YFP, no digital magnifications of these cells are shown. The images shown are
representative of at least 3 independent transfection experiments. Scale bar = 50 μm. Images were capture on a standard fluorescence
microscope.
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were very similar to that of cells expressing WT SOD1
(Figures 8A and 8B). As was observed in cells expressing
WT SOD1, there were still relatively high levels of
detergent-soluble, cell-associated, A4V SOD1 after sapo-
nin treatment (Figure 8B). This detergent-soluble
mutant protein may be protein that diffused into the
nucleus. Importantly, in cells expressing the A4V
mutant, saponin treatment did not significantly reduce
the amount of detergent-insoluble mutant protein asso-
ciated with the cells (Figure 8B). Similar outcomes were
observed in cells treated with digitonin (Additional File
1, Figure S6), which similar to saponin, permeabilizes
cell plasma membranes without completely lysing cells.
These findings indicate that the majority of the insoluble
mutant SOD1 in cells is immobilized by association with
some cytosolic structure.
Based on the findings above, we were confident that a
substantial portion of mutant SOD1 aggregates are not
extracted by saponin treatment. Therefore, we applied
these techniques to HEK293FT cells transfected with
expression vectors for untagged SOD1. Twenty-four
hours post-transfection, saponin-treated cells were fixed
and immunostained with the SEDI and C4F6 antibodies
(Figure 9). Neither antibody detected cytosolic reactivity
in cells expressing WT hSOD1 (Figures 9A-D), indicat-
ing that the cytosolic immunoreactivity detected with
this antibody (see Figures 1 and 2) is released into the
medium by saponin. In cells expressing A4V hSOD1,
the diffuse staining seen in untreated cells with both
antibodies (see Figure 2) was also lost. Instead we were
now able to clearly identify cells with punctate cytosolic
structures that were reactive to SEDI antibody (Figures
9E-F and 9I-L). By contrast, the C4F6 antibody did not
detect these punctate structures (Figures 9G and 9H).
These findings were consistent with what was observed
in cells expressing SOD1::YFP fusion proteins and indi-
cate that the SEDI antibody is useful in detecting
mutant SOD1 in inclusion structures.
Mutant SOD1 aggregation and toxicity
Previous studies by Matsumoto et al [31], in a PC12 cell
model of transient transfection, have demonstrated that
cells harboring inclusions formed by YFP fusions of
G85R and G93A SOD1 become permeable to propidium
iodide (a reporter of cell death). We sought to determine
whether our cell models of aggregation show evidence of
toxicity, using two reporters systems of cell death. We
initially used the CHO cells because we found these cells
to be more suited to viewing individual cells; they were
less prone to clumping, exhibited a flatter morphology,
and showed better adherence (meaning fewer were lost
during various steps in preparation). The YFP tagged var-
iants of mutant SOD1 facilitate direct visualization of
whether cells that harbor aggregates are undergoing
degeneration. To assess whether cells expressing mutant
or WT::YFP SOD1 fusion proteins might be dying, we
used a cell death assay based on uptake of a homodimer
of ethidium bromide. Cells that have lost membrane
integrity take up the ethidium homodimer and fluoresce
red upon binding of the ethidium to nucleic acids. We
observed only low levels of cell death in cells expressing
A4V::YFP SOD1 fusion proteins with similar levels
occurring in cells expressing WT::YFP SOD1 fusion pro-
teins and untransfected cells (Figure 10). Only rarely did
we observe cells harboring A4V::YFP SOD1 inclusions
showing uptake of ethidium homodimer. Importantly, in
these studies, cells showing diffuse distributions of
mutant or WT::YFP SOD1 fusion proteins also lacked
evidence of obvious increases in uptake of the cell death
marker. A similar outcome was obtained in the
HEK293FT cell model (Additional File 1, Figure S7).
We also assessed whether cells with inclusion showed
markers of apoptosis, using a TUNEL assay. For this
experiment we used only the CHO cell model because
the HEK293FT cells were so poorly adherent through
processing steps that we could not make unbiased
observations. At 48 hours post-transfection, we found
that relatively few CHO cells were positive and only
rarely did we observe TUNEL labeling of cells that
expressed A4V::YFP SOD1 fusion proteins (Additional
File 1, Figure S8). A similar low frequency of TUNEL
positive cells was seen in cells expressing WT::YFP
SOD1 fusion proteins and untransfected cells (Addi-
tional File 1, Figure S8). Overall, we observed no
Figure 7 Saponin treatment extracts cytosolic SOD1
immunostaining. HEK293FT cells were transfected with vectors for
WT (A, B) or A4V SOD1 (C, D) and after 24 hours treated with
saponin for 30 minutes at a concentration of 0.01% in 1× PBS. The
cells were then fixed and immunostained as explained in Methods.
Images were captured on a standard fluorescence microscope with
an immersion oil 100× objective. All bars represent 20 μm. The
images shown are representative of at least 3 independent
transfection experiments.
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obvious overlap between cells expressing WT or A4V
SOD1::YFP fusion proteins (whether inclusions were
present or absent) and either marker of apoptosis or
death. We conclude that these cells show limited toxi-
city in response to the expression of the fusion proteins.
Discussion
In the present study, we use a combination of natural
SOD1 mutants and SOD1::YFP fusion proteins with
conformationally-restricted antibodies to examine the
relationships between mutant SOD1 misfolding, aggre-
gation, and inclusion body formation. Our findings are
consistent with a scenario in which mutant SOD1 is
capable of adopting a continuum of structures that
include soluble non-natively folded proteins, detergent-
insoluble multimeric complexes, and larger inclusion
bodies. We observe that mutant SOD1 can adopt con-
formations that remain soluble in aqueous buffers and
are freely mobile and yet are recognized by conforma-
tionally-restricted antibodies such as the SEDI and C4F6
antibodies. As previously described, we observe that
mutant SOD1 adopts a conformation that promotes its
assembly into larger structures that are not soluble in
non-ionic detergents and sediment by centrifugation. In
Figure 8 Detergent-insoluble forms of mutant SOD1 remain cell associated after saponin treatment. A) Immunoblots of HEK293FT cells
that were transfected with the indicated SOD1 constructs for 48 hours. Prior to harvest, cells were incubated 30 minutes in PBS with 0.01%
saponin. The harvested cell pellets were analyzed by detergent extraction and centrifugation assays (S1 fractions, each lane contains 5 μg of
total protein; P2 fractions, each lane contains 20 μg of total protein). The amount of SOD1 protein released into the cell media was also
evaluated (each lane loaded with 5 μg of total protein). B) Quantification of SOD1 protein found in the Media, P2 and S1 fractions of cells
untreated or treated with saponin (Sap.), and expressing WT or A4V. Symbols over bars indicate differences from corresponding non-treated
control. Unpaired t-tests: *p ≤ 0.05. The data were averaged from at least 3 independent transfection and immunoblotting experiments.
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cells expressing untagged versions of mutant SOD1,
using conformationally restricted antibodies, we found
that the accumulation of detergent-insoluble protein
correlated with the appearance of small punctuate struc-
tures that could be viewed as small micro-aggregates.
These structures were recognizable by the SEDI anti-
body, but not by the C4F6 antibody. Moreover, although
the accumulation of detergent-insoluble mutant protein
correlated with the appearance of inclusion like struc-
tures for mutant SOD1, we found an example in which
detergent-insolubility and inclusion formation was disso-
ciated. Large amounts of detergent insoluble WT::YFP
we detected in cells expressing this SOD fusion protein
but inclusion structures were rarely visualized. Notably,
this detergent-insoluble protein was, however, freely
mobile and could be released by saponin. This finding
indicates that SOD1 in detergent-insoluble conforma-
tions may not necessarily be assembled into large inclu-
sion structures and can remain freely mobile. Thus, we
demonstrate that mutant SOD1 has the capacity to pro-
duce a continuum of structures with each exhibiting fea-
tures that are selectively revealed depending upon the
detection methods used.
SOD1 conformation and antibody epitope accessibility
In this report, we used three previously described anti-
bodies that each show restricted reactivity to native
conformations of SOD1. For the hSOD1 and SEDI anti-
bodies, previous studies have demonstrated that these
antibodies are not capable of immunoprecipitating
natively folded WT SOD1 [17,26]. The C4F6 antibody
has been shown to react poorly with natively folded WT
SOD1 in immunoblots of non-denaturing SDS-PAGE
[27]. The hSOD1 antibody, which was raised against
specific peptide sequences of human SOD1 (residues
24-36), recognized soluble, freely mobile, forms of both
WT and mutant SOD1. In work that will be published
elsewhere, we have found that the vast majority of WT
or mutant SOD1 that is over-expressed in these cells
does not contain Cu (H. Lelie and D Borchelt, unpub-
lished observation). We thus suggest that the lack of
bound Cu in the normal active site produces a confor-
mational change that exposes the hSOD1 epitope (aa
24-36). However, as the protein organizes into inclu-
sions, this epitope becomes inaccessible, indicating that
this portion of the protein must be buried within very
stable structures in the inclusions.
An antibody termed C4F6, which was raised against
the G93A variant of human SOD1, did not recognize
inclusion structures formed by either untagged or YFP-
tagged proteins. The epitope for the C4F6 antibody is
complex. Under denaturing conditions, this antibody
behaves as if the epitope includes the specific mutation
of Gly 93 to Ala [27]. On denaturing immunoblots,
Figure 9 The SEDI antibody recognizes immobile punctate structures in cells expressing A4V hSOD1. HEK293FT cells were transiently
transfected with expression plasmids for either WT (A-D) or A4V (E-L) hSOD1 for 24 hours and stained with the SEDI or C4F6 antibody as
explained in Methods. Pictures were taken with a 40x objective. Scale bars = 10 μm. The images in I-L were digitally magnified from A4V SOD1
cells stained with SEDI/DAPI. The images shown are representative of at least 3 independent transfection experiments.
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C4F6 shows high specificity to the G93A variant with no
reactivity to WT or other FALS associated mutations at
Gly 93 [27]. However, under non-denaturing conditions,
the antibody behaves as if the epitope includes
conformational elements as the antibody can recognize
other mutant forms of SOD1, albeit much less robustly
[24]. The antibody shows no reactivity to native WT
SOD1 [27]. Thus, although it is likely that the
Figure 10 CHO cells expressing A4V::YFP SOD1 fusion protein do not show evidence of increased membrane permeability. To assess
whether aggregates of mutant SOD::YFP fusion proteins induce cell death, CHO cells were transiently transfected with expression vectors for
SOD1 A4V::YFP (A and B) and WT::YFP (C). After 48 hours, the cells were incubated with dimeric ethidium bromide (EtBr) as described in
Methods. Images were captured at 40× magnification (scale bar = 50 μm). Overall, there were few cells that showed evidence of increase
membrane permeability with no obvious difference between cultures transfected with the 2 constructs or untransfected cells (D). As a positive
control, untransfected cells were treated with staurosporine (+Str) to induce death and stained with dimeric ethidium bromide (D).
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conformational elements recognized by this antibody are
in proximity to the primary epitope that includes Gly
93, within exon 4, the epitope has not been precisely
defined.
Our findings indicate that as mutant SOD1 assembles
into inclusions, there is a conformational shift that
either masks or destroys the C4F6 epitope. We note,
however, that Okamato et al [39] reported that inclu-
sions in the spinal cords of G93A mice were immunor-
eactive with the C4F6 antibody. It is possible that
reactivity with inclusions in the G93A mice is unique to
this model because the non-conformational elements of
the epitope include the G93A mutation [27].
In our cell culture models, the SEDI and C4F6 antibo-
dies showed the best discrimination between WT and
mutant SOD1 in regard to the diffuse cytosolic staining.
Although there were rare cells expressing WT SOD1
that showed reactivity, the frequency with which mutant
cells were immunostained was much higher. The signifi-
cance of the infrequent, but robust, staining of cells
expressing WT SOD1 with these antibodies is uncertain.
Bosco and colleagues recently reported that C4F6 will
react with oxidatively modified WT SOD1 [27]. Thus, it
is possible that some type of oxidative process in a sub-
set of cells triggers the misfolding of WT SOD1. It is
also possible that WT SOD1 can spontaneous misfold
in rare cases of extreme over-expression with the mis-
folded conformation propagating throughout the cell.
In cells expressing the untagged A4V SOD1, both the
C4F6 and SEDI antibodies robustly detected a diffusely
distributed form of mutant SOD1 that was readily
released from cells by saponin. We note that Zetter-
strom and colleagues have demonstrated that spinal
cord tissues from mice expressing both WT and mutant
human SOD1 contain varied amounts (higher in mutant
mice) of soluble SOD1 that aberrantly binds hydropho-
bic media and lacks normal intramolecular disulfide
bonds [40]. Thus, there are multiple lines of evidence to
indicate soluble malfolded forms of mutant protein exist
at least transiently. Whether these soluble malfolded
forms of mutant SOD1 are precursors of the aggregates
that form or a misfolded soluble entity that is off path-
way for aggregation is uncertain.
In comparing the C4F6 and SEDI antibodies, each
have unique utility. The SEDI antibody would appear to
be a very good antibody for labeling inclusion structures.
Although this antibody is conformationally-restricted in
reactivity as it does not recognize natively folded
dimeric WT SOD1 [17], it is not a conformation specific
epitope; this antibody will recognize denatured WT
SOD1 and could presumably recognize an immature
form of SOD1 in a monomeric state that is on pathway
for native folding. In our hands, the C4F6 antibody
seems to behave more like a conformation specific
antibody in that it does not recognize denatured WT
SOD1 or denatured forms of mutant SOD1, except for
specific reactivity with denatured G93A SOD1 [27].
While this later finding would indicate reactivity with a
specific mutant sequence of SOD1 (the G93A mutation
and flanking sequence), the reactivity of C4F6 with dif-
fusely distributed cytosolic SOD1 in cells expressing
A4V SOD1 is consistent with the antibody recognizing a
specific mal-folded conformation as opposed to simply
recognizing an immature form of mutant SOD1 or a
specific sequence epitope. Thus, the C4F6 antibody may
be uniquely valuable in identifying mal-folded SOD1
proteins. Interestingly, Bosco et al described diffuse
labeling of motor neurons of sporadic ALS cases with
the C4F6 antibody, suggesting that misfolding of WT
SOD1 occurs at some point in the course of sporadic
disease [27].
We note, however, that Karumbayaram and colleagues
used C4F6 in immunostains of ES cell-derived motor
neurons expressing WT, A4V, I113T, and G93A
mutants, finding that the antibody specifically recog-
nized cells expressing the G93A variant [41](Additional
File 1, Table S1). In this study, it appears that the
sequence specific epitope of the C4F6 antibody predo-
minated. The level of mutant SOD1 expression in these
cells was not characterized and it is difficult to explain
why the ES-motor-neuron cell model did not show the
misfolding of other mutants that were expressed.
Immunohistochemical analyses of transgenic mouse
models and human ALS with conformationally restricted
antibodies
The hSOD1 antibody has been extensively used in
immunohistochemical analyses of spinal cord tissues
from mice expressing WT and mutant SOD1 with the
pattern of immunoreactivity showing some variability
depending upon how the tissues were prepared (Addi-
tional File 1, Table S1). Generally, the antibody shows
cell body reactivity that is similar to what we have
described here in our cell model in tissues from mutant
SOD1 transgenic mice when the tissues have been pre-
pared for immunohistochemistry by cryoprotection and
frozen sectioning, with no antigen retrieval (Additional
File 1, Table S1). Immunolabeling of cell bodies in
mutant mouse tissues prepared by paraffin embedding
with microwave heating for antigen retrieval has gener-
ally been weak, but there are also examples of robust
cell body immunoreactivity (Additional File 1, Table S1).
The only published example of immunostaining of tis-
sues from mice that over-express WT SOD1 utilized a
paraffin embedding method with microwave heating for
antigen retrieval, finding relative weak labeling of cell
bodies with diffuse neuropil immunoreactivity [42].
Importantly, hSOD1 antibody has consistently been
Prudencio and Borchelt Molecular Neurodegeneration 2011, 6:77
http://www.molecularneurodegeneration.com/content/6/1/77
Page 13 of 18
found to show little or no reactivity with inclusion
structures (Additional File 1, Table S1).
The C4F6 and SEDI antibodies have also been used in
studies of tissues from human ALS and SOD1 mouse
models, though not as extensively in the case of the
C4F6 antibody. Okamato reported intense immunoreac-
tivity in cell bodies of the G93A mice with the C4F6
antibody, with labeling of structures interpreted as
inclusions [39](Additional File 1, Table S1). The degree
to which this pattern of staining reflects the mutation
specific component (G93A) of the C4F6 epitope is
uncertain. Our data would indicate that C4F6 does not
readily recognize inclusions formed by other fALS var-
iants of SOD1. The SEDI antibody has been used in stu-
dies of mice expressing the G37R, G85R, and G93A
mutants as well as human fALS and sALS cases [17]
(Additional File 1, Table S1). In the G85R mice and
human fALS associated with A4V, A4T, I113T, V14M,
and dG27/P28 mutations, SEDI antibody showed intense
reactivity to inclusion structures in cell bodies. However,
in mice expressing the G37R and G93A mutants, SEDI
antibody primarily immunostained the margins of
vacuolar pathology that is prevalent in these animals
[17]. If inclusions were also present in the spinal cords
of these mice, they were not selectively recognized.
Overall, these findings are consistent with our results
and indicate the utility of the SEDI antibody in detecting
mutant SOD1 inclusion pathology. It is noteworthy that
spinal cord tissues from sALS patients lacking mutations
in SOD1 show little or no reactivity with the SEDI anti-
body [43]. However, Forsberg and colleagues reported
that an SOD1 antibody raised against a C-terminal pep-
tide that included the epitope of the SEDI antibody
immunostained small punctate inclusion structures in
motor neurons of sALS cases as well as non-SOD1
fALS cases [44]. Whether differences in antibody specifi-
city or differences in tissue preparation account for the
different outcomes is unknown and the potential invol-
vement of misfolded WT SOD1 within motor neurons
in sALS remains a debated topic.
Aggregation and toxicity
In the cell models we use here to examine mutant
SOD1 folding, we observe very low levels of cell death
by the methods we used to detect dying cells. This find-
ing indicates that misfolded and aggregated forms of
mutant SOD1 are not acutely toxic in these cell models.
We focused effort on models in which SOD::YFP fusion
proteins were expressed so that we could definitively
identify transfected cells. Cells harboring inclusions gen-
erally lacked evidence of impending death and very little
evidence of toxicity was noted in cells showing more
diffuse distributions of SOD::YFP fusion proteins.
Although, it is possible that cells that died detached
from the plate quickly and escaped detection by our
methods, we are left with no clear indication of toxicity.
Several previous studies have sought to determine
whether aggregates of mutant SOD1 are associated with
toxicity in a variety of neural cell models. We are aware
of only two studies that have used methods that would
allow for simultaneous assessment of aggregation (via
expression of YFP fusion proteins) and visual reporters
of cell toxicity. Using a rat PC12 cell model, which can
be differentiated into neuron-like cells, and time-lapse
analysis, Matsumoto et al [31] observed that cells that
formed inclusions of SOD1::YFP fusion proteins were
much more likely to die. However, cell death was also
observed in cells lacking inclusions. Zhang and Zhu
examined toxicity in NSC34 cells, which were created
by fusion of murine neuroblastoma cells and murine
motor neurons [45], finding no evidence for direct toxi-
city despite the presence of aggregates in cells expres-
sing mutant SOD1 fused to GFP [29]. In this study,
NSC34 cells stably expressing mutant SOD::GFP fusion
proteins were reported to be more sensitive to oxidative
stress induced by low levels of H2O2, but there was no
reported examination of whether cells with inclusions
were specifically more sensitive. A similar lack of direct
toxicity by mutant SOD1 fused to eGFP when expressed
in NSC34 cells was reported by Turner et al. [33].
There are two reports describing the expression of
mutant SOD1 fused to GFP in mouse neuroblastoma
N2a cells. One study reported finding a correlation
between expression of mutants that readily form inclu-
sions and toxicity (MTT assay) [46]. In this study,
experimental mutations that changed cysteine residues
at position 6 and 111 reduced aggregation and reduced
toxicity. In a second study, Witan et al [47] failed to
observe direct toxicity due to expression of mutant
SOD1 fusions with EGFP despite detection of inclusions
at high frequency. However, similar to Zhang and Zhu
[29], Witan et al reported that cells expressing the
mutant fusion proteins were more sensitive to oxidative
stress inducing agents [47]. The authors did not investi-
gate whether cells with inclusions were specifically more
sensitive to oxidative stress. The study by Witan differs
from all others in that the fusion proteins expressed
were engineered as contiguous homodimers or contigu-
ous heterodimers (mutant with WT). Overall, the out-
comes of these investigations provide a mixed view of
the role of mutant SOD1 aggregation in toxicity, and it
remains difficult to explain divergent outcomes.
In previous work in transgenic mice there has been
much effort to define changes in the physical nature
mutant SOD1 through the course of disease. In an ele-
gant study by Wang and colleagues, expression of a
G85R variant of human SOD1 fused to YFP clearly
demonstrated that large visible inclusions form very late
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in the course of disease [48]. In our previous studies of
transgenic mouse models of ALS expressing untagged
variants of mutant SOD1, we have similarly observed
that the greatest accumulation of detergent-insoluble
aggregates of mutant SOD1 occurs late in disease pro-
gression [22]. In the G93A-Gur1 model, which reaches
end-stage paralysis at about 120 days, aggregates begin
to accumulate between 90 and 105 days and then rise
dramatically as the animals approach endstage [22].
During this same interval, serum levels of neurofilament
H, which serve a biomarker of axonal degeneration [23],
similarly rise dramatically. Thus we can correlate aggre-
gation of mutant SOD1 and axonal degeneration in the
animal models. Moreover, in the G93A model, the
majority of motor neuron death occurs during the inter-
val in which detergent-insoluble aggregates appear.
Although it is tempting to link inclusion formation to
motor neuron death, it remains difficult to assign
mutant protein aggregation as causative of cell death as
it is possible that the accumulation of aggregates serves
as a biomarker of cellular degeneration in which the
cells simply lose the ability to prevent the misfolded
mutant protein from aggregating because of some com-
bination of declining chaperone activities, declining pro-
teasome activity to degrade the misfolded protein, or
declining energy production to support these activities.
It may not be possible to sort out the role of aggrega-
tion in toxicity until we have tools to prevent such
aggregates from occurring in vivo [49].
Although we might wish to be able to assign toxicity
to a specific conformation, assembly, or aggregate of
mutant SOD1, it seems likely that multiple forms of
misfolded SOD1 exert deleterious effects. For example,
it is fairly well established that early, during the insi-
dious phase of disease when pathologic abnormalities
are observed with limited symptoms, there is limited
accumulation of the detergent-insoluble aggregates;
instead, detergent soluble forms of mutant SOD1 predo-
minate [22]. As mentioned above, a previous study by
Zetterstrom et al demonstrated that early in the course
of disease, spinal cords of mice expressing mutant
SOD1 contain soluble forms of mutant SOD1 that bind
to hydrophobic affinity chromatography media and lack
the normal intramolecular disulfide linkage [40].
Whether these non-natively folded forms of mutant
SOD1 mediate early events in toxicity remains to be
established, their early appearance in tissues from the
mutant mice clearly makes them candidates. Our find-
ings indicate that the C4F6 antibody might be useful in
detecting soluble misfolded forms of mutant SOD1 early
in the course of disease. However, we would recom-
mend that such studies focus on mutants other than the
G93A mutant to avoid mutation specific reactivity in
favor of misfolded confirmation reactivity. It would, of
course, be easier to explain the disease if one specific
form of mutant SOD1 (monomer, oligomer, aggregate,
or inclusion) targeted one specific process that is unique
to neurons and of greater importance to motor neurons,
but the available evidence suggests multiple systems
may be targets of mutant SOD1 toxicity [50].
Conclusions
The present study uses a combination of natural SOD1
mutant and SOD1::YFP fusion proteins to examine the
relationships between detergent insoluble structures,
aggregates, and inclusion body formation. Studies in
mice, using both biochemical methods of detection and
YFP tagging methods have established that larger aggre-
gates form late in the disease, primarily during the time
of robust cell death and rapid disease progression
[22,48]. However, these studies also establish that patho-
logic and behavioral symptoms occur in mice prior to
the accumulation of these larger aggregates, implying
that smaller assemblies of mutant SOD1 must mediate
some aspect of toxicity and trigger disease. Our studies
define the utility of different approaches in detecting
mal-folded forms of WT and mutant SOD1 that are
both soluble and insoluble. Going forward, it may be
possible through the use of these various tools to better
define the role of these various assemblies of mutant
SOD1 in the evolution of pathologic and behavioral
abnormalities that define the ALS mouse models.
Methods
SOD1 cDNA expression plasmids and cell lines
WT and mutant hSOD1 untagged proteins were
expressed from plasmids based on the mammalian pEF-
BOS expression vector, and have been previously
described [1,16,20,21]. YFP tagged SOD1 cDNA variants
were created from a worm expression vector (pPD30.38)
that contains WT hSOD1 fused to eYFP (yellow fluores-
cent protein) kindly provided by Dr. Rick Morimoto
(Northwestern University). WT::YFP, WT::RFP and YFP
variants have been previously described [35], and
mutant fluorescently tagged SOD1 variants were con-
structed following similar procedures.
All cell culture studies of SOD1 aggregation used
HEK293FT cells (Invitrogen, Carlsbad, CA), mouse TK-
L cells, or CHO cells (ATCC, Manassas, VA) as indi-
cated, which were maintained following ATCC
recommendations.
Transfections
Transfection of cells for immunocytochemistry was per-
formed on glass coverslips that were previously coated
with 0.5 mg/ml poly-L-lysine in 1× phosphate buffered
saline solution (PBS). A total of 2 μg of vector DNA was
transfected per well, using Lipofectamine 2000
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(Invitrogen, Carlsbad, CA). For biochemical analyses, a
total of 4 μg of vector DNA was used to transfect cells
in 60 mm poly-L-lysine coated dishes (BD Biosciences,
Bedford, MA). Each transfection experiment was
repeated a minimum of 3 times.
Immunocytochemistry
Transfected cells were either fixed with 4% paraformal-
dehyde in 1× PBS solution for 15 minutes or incubated
for 30 minutes in mild detergents (0.01% digitonin or
0.01% saponin in 1× PBS) prior cell fixation. Cells were
then completely permeabilized using cold 100% metha-
nol for 5 minutes followed by incubation in 20% normal
goat serum in 1× PBS and immunostaining with hSOD1
(1:500), SEDI (1:500), or C4F6 (1:500) antibodies over-
night (in 1× PBS with 10% normal goat serum). Primary
antibodies were visualized with secondary fluorescently-
labeled antibodies (1:2000) diluted in same buffer as the
primary antibody (Alexafluor goat anti-rabbit 594 nm
for hSOD1 or SEDI, or Alexafluor goat anti-mouse 568
nm for C4F6 antibody; Invitrogen, Carlsbad, CA). To
visualize nuclei, cells were treated with DAPI solution
(4’,6-diamidino-2-phenylindole, dihydrochloride, stock
14.3 mM from Invitrogen, Carlsbad, CA) at a dilution of
1:2000 for 10 minutes. Fluorescence was visualized
using an Olympus IX81-DSU spinning disk confocal
microscope or an epifluorescence Olympus BX60 micro-
scope as indicated in the Figure Legends.
Detergent extraction of SOD1 aggregates
Extraction of cultured cells in nonionic detergents (NP-
40) was performed as described previously [1,21,22].
The procedure produces two protein fractions termed
S1 (detergent-soluble) and P2 (detergent-insoluble),
which were then analyzed by immunoblotting (5 μg
total protein from S1 is compared to 20 μg total protein
from P2). We then quantified the intensity of the SOD1
bands in each fraction and calculated the mean ratio of
insoluble to soluble protein. Data were then analyzed on
GraphPad PRISM 5.01 Software (La Jolla, CA) to deter-
mine statistical differences, using unpaired student t-
tests, and generate graphic representations.
Cell Death Assays
To assess nuclear DNA fragmentation, we used TUNEL
labeling assays (In Situ Cell Death Detection Kit, Roche
Applied Science, cat# 12 156 792 910, Indianapolis, IN,
USA). Briefly, CHO cells were plated into 12-well plates
containing lysine-coated coverslips and grown overnight.
The cells were then transfected with 0.8 μg DNA in 2 μl
of Lipofectamine 2000 diluted, ultimately in 500 μl of
Opti-MEM. After 3 h at 37°C, 500 μl of complete media
(Ham’s F12 with 10% fetal bovine serum and 2 mM L-
glutamine) was added. For a positive control, one well
of untransfected cells was treated with staurosporine 1
or 2 μM final concentration, (40 μl or 80 μl of a 50 mM
stock in 1 ml media) overnight at 37°C. Twenty-four
hours after transfection, cells were rinsed 3 times with
1× PBS, fixed in 4% paraformaldehyde in 1× PBS for 20
min at RT, and then rinsed 3 times in 1× PBS. Before
immunostaining, the cells were permeabilized in pre-
heated 10 mM Tri-sodium citrate and 0.05% Tween 20
(pH 6.0) for 10 min at 90 C, and then rinsed 3 times in
1× PBS.
For TUNEL labeling, we followed the manufacturer’s
protocol, which entails making a reaction mixture by
mixing 8 μl of enzyme solution into a 72 μl labeling
solution that is kept in the dark on ice until ready to
use. Each coverslip was then incubated in the labeling
solution by pipetting 18 μl of the solution mix onto half
of the coverslips, which was then covered with a piece
of parafilm to keep it from drying out. The other half of
the coverslips were covered 18 μl of labeling solution
with no enzyme for a negative control (also covered
with parafilm). All coverslips were incubated in a humid
chamber at 37°C for 2 - 2.5 hours before rinsing 3 times
with 1× PBS followed by floating off and removing the
parafilm. Coverslips were then mounted on glass slides
using Aqua-Poly/Mount (Polysciences, Inc., Warrington,
PA, USA, cat # 18606) and photographed.
A second assay for cell death utilized the LIVE/DEAD
Viability/Cytotoxicity Kit for mammalian cells [Invitro-
gen (Molecular probes), Carlsbad, CA, USA, cat #
L3224]. For this assay, cells were grown on coverslips
and transfected as described above. Positive control
cells, treated with staurosporine, were also generated as
described above. After 24 or 48 hours of incubation, the
cells were rinsed 3 times with 1× PBS and then incu-
bated with Component B of the kit (Ethidium homodi-
mer-1) at 5 or 10 μM in 1× PBS at room temperature
or 37°C for 10 to 30 minutes. The coverslips were then
rinsed in 1× PBS, mounted on glass slides and sealed
using clear nail polish before photography. We also
found that after removal of excess reagent, the cells
could be fixed in 4% paraformaldehyde and visualized.
Additional material
Additional file 1: Supplementary Figures S1-8; Supplementary Table
1. Suppl. Figure 1. The majority of SOD1 in transiently-transfected
HEK293FT transfected cells is soluble in non-ionic detergent. Suppl.
Figure 2. Formic acid treatment does not allow visualization of inclusions
using a hSOD1 antibody. Suppl. Figure 3. TK negative cells transfected
with SOD1 constructs for 48 hours and stained for human SOD1. Suppl.
Figure 4. HEK293FT cells expressing a SOD1::YFP variant accumulate
detergent-insoluble aggregates. Suppl. Figure 5. Digitonin treatment in
TK negative cells reveals a punctate pattern of SOD1 immunoreactivity in
cells expressing either WT or A4V SOD1. Suppl. Figure 6. Digitonin
extracts a portion of the detergent-soluble hSOD1 protein expressed in
HEK293FT cells. Supplemental Figure 7. EtBr uptake assay of cell
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permeability in HEK293FT cells expressing mutant and WT YFP fusion
proteins. Suppl. Figure 8. Assessment of cell death in CHO cells
expressing WT and A4V SOD::YFP fusion proteins. Supplementary Table 1.
Summary of previous findings with conformationally-restricted antibodies
[4,5,15,17,26,27,39,41-43,51-56].
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